Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Jun 3, 2026
- Accession no.
- 0001636282-26-000077
- Filed
- Jun 3, 2026
- Trade date
- Jun 1, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.06M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | SSaleDisposed | −3,557 | $69.40 | −$246,855.8 | 608,983 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −8,149 | $70.50 | −$574,504.5 | 600,834 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −3,294 | $71.38 | −$235,125.72 | 597,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.